4-propionyloxy-4-phenyl-n-methylpiperidine has been researched along with Esophageal Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bode, AM; Chen, H; Dong, Z; Jiang, Y; Li, H; Li, W; Liu, K; Ma, WY; Oi, N; Reddy, K; Saleem, M; Sheng, Y; Wu, Q; Yao, K; Zhang, Y | 1 |
1 other study(ies) available for 4-propionyloxy-4-phenyl-n-methylpiperidine and Esophageal Neoplasms
| Article | Year |
|---|---|
PPMP, a novel tubulin-depolymerizing agent against esophageal cancer in patient-derived tumor xenografts.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Esophageal Neoplasms; G2 Phase Cell Cycle Checkpoints; Humans; M Phase Cell Cycle Checkpoints; Male; Meperidine; Mice; Middle Aged; Models, Molecular; Tubulin; Tubulin Modulators; Xenograft Model Antitumor Assays | 2016 |